英国2型糖尿病患者非手术牙周治疗的成本效益
本研究从英国医疗服务提供者视角,对2型糖尿病合并牙周炎患者终身牙周治疗成本建模,并利用已发表模拟模型估算糖化血红蛋白变化对糖尿病治疗成本和健康调整预期寿命的影响。结果显示,58岁男性、糖化血红蛋白7%-7.9%时,增量成本效果比为每质量调整生命年28000英镑,结论对牙周治疗对糖化血红蛋白的效应等假设敏感。
要点
- 非手术牙周治疗可能对2型糖尿病患者具有成本效益。
- 成本效益结论依赖糖化血红蛋白改善能否长期维持。
- 患者维护治疗依从性和治疗反应比例是关键影响因素。
核心结论
- 若糖化血红蛋白改善可维持,牙周治疗对英国2型糖尿病患者在可接受的成本效果阈值内可能具成本效益。
研究设计与样本
- 从英国医疗服务提供者视角,对2型糖尿病合并牙周炎患者队列的终身牙周治疗成本进行建模。
- 利用已发表模拟模型估算糖化血红蛋白变化对糖尿病治疗成本和健康调整预期寿命的影响。
- 将成本与结局合并估算增量成本效果比。
主要发现
- 58岁男性、糖化血红蛋白7%-7.9%时,增量成本效果比为每质量调整生命年28000英镑。
- 结果对牙周治疗对糖化血红蛋白影响的假设、维护治疗依从患者比例及依从患者治疗反应比例特别敏感。
关键数值与推荐
- 增量成本效果比为每质量调整生命年28000英镑(58岁男性,糖化血红蛋白7%-7.9%)。
临床怎么用
- 在假设糖化血红蛋白改善可维持的前提下,可考虑对2型糖尿病合并牙周炎患者提供非手术牙周治疗和严格维护治疗。
局限性
- 结论高度依赖糖化血红蛋白改善可持续性的假设。
- 结果对维护治疗依从性和治疗反应比例等参数敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Periodontal therapy has been shown to reduce glycated haemoglobin in patients with diabetes, although considerable uncertainty remains regarding the sustainability of such changes. We evaluate the cost-effectiveness of non-surgical periodontal therapy and rigorous maintenance treatment in patients with type 2 diabetes and periodontitis from a provider perspective in the UK. METHOD: Lifetime costs relating to periodontal treatment were modelled for a cohort of patients with type 2 diabetes. The projected lifetime impact of changes in glycated haemoglobin on diabetes treatment costs and quality adjusted life expectancy were estimated from a published simulation model. Costs and outcomes were combined to estimate the Incremental Cost-Effectiveness Ratio for periodontal therapy in patients with type 2 diabetes. RESULTS: The Incremental Cost-Effectiveness Ratio was £28,000 per Quality Adjusted Life-Year for a man aged 58 with glycated haemoglobin of 7%-7.9%. The results were particularly sensitive to assumptions on the impact of periodontal therapy on glycated haemoglobin, the proportion of patients who comply with maintenance therapy and the proportion of compliant patients who respond to treatment. CONCLUSION: Assuming improvements in glycated haemoglobin can be maintained, periodontal therapy may be cost-effective for patients with type 2 diabetes at acceptable cost-per-Quality Adjusted Life-Year thresholds in the UK.
引用
- Solowiej-Wedderburn J, Ide M, Pennington M, et al. Cost-effectiveness of non-surgical periodontal therapy for patients with type 2 diabetes in the UK. J Clin Periodontol. 2017. PMID: 28504365. doi:10.1111/jcpe.12746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。